Neuroleptic malignant syndrome following COVID-19 vaccination.

Alfishawy, Mostafa; Bitar, Zouheir; Elgazzar, Amr; Elzoueiry, Mahmoud

Alfishawy, Mostafa; Bitar, Zouheir; Elgazzar, Amr; Elzoueiry, Mahmoud.

Alfishawy M; Infectious Diseases Consultants and Academic Researchers of Egypt (IDCARE), Egypt. Electronic address: malfishawy@kasralainy.edu.eg.
Bitar Z; Ahmadi Hospital of Kuwait Oil Company, Kuwait City, Kuwait.
Elgazzar A; Ahmadi Hospital of Kuwait Oil Company, Kuwait City, Kuwait.
Elzoueiry M; Ahmadi Hospital of Kuwait Oil Company, Kuwait City, Kuwait.

Am J Emerg Med ; 49: 408-409, 2021 11.

Article in English | MEDLINE | ID: covidwho-1091976

Subject(s)

COVID-19; Neuroleptic Malignant Syndrome; COVID-19 Vaccines; Humans; Neuroleptic Malignant Syndrome/diagnosis; Neuroleptic Malignant Syndrome/etiology; SARS-CoV-2; Vaccination/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neuroleptic Malignant Syndrome Type of study: Diagnostic study Topics: Vaccines Limits: Humans Language: English Journal: Am J Emerg Med Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google